Abacavir (Ziagen): Research: 1998-2001

Diverse Effects of NRTI-Associated Mutations on Resistance to Abacavir, Stavudine and Zidovudine in the ZORRO Trial (December 18, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from TheBodyPRO.com
Virologic Response to Abacavir/Efavirenz/ddI + Hydroxyurea in Subjects Failing Initial NRTI + PI Therapy (NZTA4008 Study) (December 18, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from TheBodyPRO.com
Simplification of Protease Inhibitor-Containing HAART Regimen With Abacavir Maintains Viral Suppression and Favorable Adherence in HIV-1 Infected Adults (October 27, 2001)
In 39th Annual Meeting of the Infectious Diseases Society of America, from TheBodyPRO.com
The Compact Quad, Combivir/Abacavir/Efavirenz -- Preliminary 48-Week Results (October 27, 2001)
In 39th Annual Meeting of the Infectious Diseases Society of America, from TheBodyPRO.com
Prospective Study of Hyperlipidemia in ART-Naive Subjects Taking Abacavir/Combivir/Nelfinavir, or Lamivudine/Stavudine/NFV (GSK Protocol ESS40002) (October 26, 2001)
In 3rd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from TheBodyPRO.com
Risk Factor Analysis of Hypersensitivity Reactions to Abacavir: Retrospective Analysis of 25 Clinical Trials (July 10, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from TheBodyPRO.com
Short-Term Immuno-Suppressive Therapy With Prednisolone in HIV-1-Infected Patients Receiving Abacavir With or Without Nevirapine (July 10, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from TheBodyPRO.com
Abacavir/Combivir Is Comparable to Indinavir/Combivir in HIV-1 Infected Antiretroviral Therapy Naive Adults: Preliminary Results of a 48-Week Open-Label Study (CNA3014) (July 10, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from TheBodyPRO.com
A Randomized Open Label Study to Investigate Abacavir and Lamivudine as Once-Daily Components of a Triple-Combination Regimen (July 9, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from TheBodyPRO.com
Comparison of Symptoms of Influenza A Infection With Abacavir-Associated Hypersensitivity Reaction (February 7, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
Epidemiological Risk Factors and Immunological Mechanisms of Hypersensitivity Reactions to Abacavir (February 7, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
Intracellular Carbovir Triphosphate Levels Among Patients Taking Abacavir Once Daily (February 7, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
Phosphorylation of Zidovudine, Stavudine, and Abacavir in Peripheral Blood Mononuclear Cells in Treatment-Naive and Treatment-Experienced Patients (February 5, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
Determination of a Clinically Relevant Phenotypic Resistance "Cutoff" for Abacavir Using the PhenoSense Assay (February 5, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
Anti-HIV Drugs Update (October 2000)
In Project Inform Perspective, from Project Inform
Abacavir vs. Indinavir in Therapy-Naive People (CNA3014) (August 17, 2000)
In STEP Ezine, from Seattle Treatment Education Project
PROTRA Study: To Evaluate the Safety and Efficacy of Abacavir and Efavirenz When Substituted for a PI in HIV-1-Infected Subjects Treated With Two NRTIs and a PI With Plasma HIV-RNA Levels Below the Limit of Assay Quantification (July 11, 2000)
In The XIII International AIDS Conference, from TheBodyPRO.com
The Multiple Nucleoside Analogue Resistance Mutations Confer Cross-Resistance to Abacavir (February 1, 1999)
In The 6th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
Abacavir for Salvage or Intensification (January 1999)
In GMHC Treatment Issues, from Gay Men's Health Crisis
Antiretroviral Effects of Therapy Combining Abacavir With HIV Protease Inhibitors (February 2, 1998)
In The 5th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com

More Most Viewed Articles

HIV Tools You Can Use

Track Your CD4 Count, Viral Load and More: Use TheBody.com's Health Tracker

TheBody.com's New! TheBody.com App
TheBody.com's Medication and Health Reminders
TheBody.com's Facebook, Widgets, RSS Feeds and Twitter
Are You at Risk for HIV? Take Our Quiz!
U.S. ASO Finder U.S. ASO Listings
International ASOs

The Body is a service of Remedy Health Media, LLC, 500 5th Avenue, 19th Floor, New York, NY 10110. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.